Targeting multidrug resistance in cancer
Gergely Szakács,Jill K. Paterson,Joseph A. Ludwig,Catherine Booth-Genthe,Michael M. Gottesman
DOI: https://doi.org/10.1038/nrd1984
IF: 112.288
2006-03-01
Nature Reviews Drug Discovery
Abstract:Key PointsThe development of simultaneous resistance to multiple drugs, with varying chemical structures and targets, is a major obstacle to effective cancer therapy.Studies indicate that there are three major mechanisms of multidrug resistance (MDR): decreased uptake of water-soluble drugs; various changes in cells that affect the ability of cytotoxic drugs to kill cells; and increased energy-dependent efflux of hydrophobic drugs.Removal of hydrophobic drugs from cells is the most commonly encountered mechanism of multidrug resistance (MDR), and ATP-binding cassette (ABC) transporters have a key role in this process.The ABC transporter family of proteins comprises seven subclasses that are labelled A–G, and these proteins have been shown to be essential for many cellular processes that require transport of substrates across cell membranes, with several members of this family being involved in the absorption, excretion and distribution of drugs.ABC transporters have broad substrate specificity, and the abundance of ABC transporter proteins goes some way to explaining the difficulties faced during the past 20 years when attempting to circumvent ABC-mediated MDR in vivo. Research has focused on the development of drugs that either evade efflux or inhibit the function of efflux transporters, and although progress in this area has been slow, the rationale for this approach is still strong.Several ABC transporters have been found to be overexpressed in cancer cell lines cultured under selective pressure, with at least 12 ABC transporters from four ABC subfamilies implicated in the drug resistance of cells maintained in tissue culture. Studies have shown that the major mechanism of MDR in most cultured cancer cells involves P-glycoprotein (Pgp; MDR1; ABCB1), multidrug resistance associated-protein 1 (MRP1, also known as ABCC1) or ABCG2.Despite significant advances in knowledge of the biochemistry and substrate specificity of ABC transporters since the first description of MDR, translation of this knowledge from the bench to the bedside has proved to be difficult. Only inhibitors of Pgp, and to a lesser extent MRP1 and ABCG2, have been evaluated in clinical trials, and the development of several inhibitors has been discontinued. However, some improved compounds are currently in clinical trials, and it is hoped that the lessons learned from earlier trials will improve the chance of success.Alternative strategies to overcome ABC-transporter-mediated MDR are also emerging, including engaging, evading or exploiting efflux-based resistance mechanisms.
pharmacology & pharmacy,biotechnology & applied microbiology